Bristol tax reporting (correction)
Bristol-Myers Squibb's incoming tax reporting controls remain a "reportable condition," according to the company's auditors, PricewaterhouseCoopers. In a story on Bristol's latest earnings restatement, "The Pink Sheet" incorrectly reported that the tax controls are considered a "material weakness." Bristol has resolved both "material weaknesses" identified by PwC a year ago (1"The Pink Sheet" March 22, 2004, p. 24)...
You may also be interested in...
Bristol-Myers Squibb still has work to do to resolve its income tax reporting processes, the company acknowledged in a 10-K filed with the Securities & Exchange Commission March 15
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.